Breast ultrasound significantly increases detection of cancers in high-risk women but takes a big toll on the rate of benign biopsies, according to the initial results of a screening trial sponsored by the American College of Radiology Imaging Network and the Avon Foundation.
Breast ultrasound significantly increases detection of cancers in high-risk women but takes a big toll on the rate of benign biopsies, according to the initial results of a screening trial sponsored by the American College of Radiology Imaging Network and the Avon Foundation.
In the ACRIN 6666 study of about 2800 women, breast ultrasound increased the detection yield over mammography by 4.2 cancers per 1000 high-risk women in a single prevalence screen, said principal investigator Dr. Wendie Berg, who presented the results at a Sept. 28 ACRIN meeting in Arlington, VA.
But the increase came at a high cost, according to the multicenter study. Mammography prompted biopsies in 2.6% of cases, and 29% of these biopsies were positive. In comparison, ultrasound prompted biopsies in 5% of cases, and only 8.8% were positive. There was also an increase in short-term follow-ups due to the addition of ultrasound.
"Women contemplating breast ultrasound screening must be aware of the substantial risk of false positives," said Berg, of American Radiology Services in Lutherville, MD.
Radiologists independently compared mammography (screen-film and digital) with a specific breast ultrasound protocol performed by well-trained practitioners. Mammography picked up 20 cancers: 12 that were not seen on ultrasound and eight that were also visible on ultrasound. Median size of mammographically detected cancer was 12 mm, and three cases were node-positive.
Ultrasound picked up 12 cancers not seen on mammography, including 11 invasive findings. Median size was favorable at 10 mm, and only one cancer was node-positive.
Surprisingly, researchers did not observe any differences in performance between the two techniques in terms of breast density. Nor did they note advantages for digital versus film mammography for detection of additional cancers, though digital had slightly higher specificity.
In a press statement, fellow ACRIN 6666 investigator Dr. Etta Pisano said that based on the study results, it is difficult to determine whether screening ultrasound is worthwhile.
Researchers had hoped to see a bigger effect of ultrasound compared with mammography. Instead, the results present a mixed picture, Pisano said.
Practical obstacles also stall utilization. Median interpretation time was 19 to 20 minutes, longer than expected. Currently, access is limited, as only 35% of facilities in the U.S. offer breast ultrasound. There is a shortage of trained technologists and physicians, and reimbursement does not cover the cost of providing the practice, Berg said. Automated breast ultrasound could prove helpful, but use of this technology would increase costs of providing the service.
For more information from the Diagnostic Imaging archives:
Italian study questions breast ultrasound's value
Doppler Ultrasound predicts chemotherapy success for breast cancer
Ultrasound proves effective for axillary staging of less common breast cancer
Breast MRI outperforms mammography and ultrasound in high-risk women
College, society drop out of surgeon-sponsored breast ultrasound accreditation program
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.